Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.

Opinion
Video

Panelists discuss time to progression by organ with lenvatinib plus + pembrolizumab in advanced renal cell carcinoma (RCC), highlighting key data and its the implications for treatment decisions.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
Related Content